J695
( DrugBank: - / KEGG DRUG: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 96 | Crohn disease | 5 |
96. Crohn disease
Clinical trials : 2,442 / Drugs : 1,278 - (DrugBank : 248) / Drug target genes : 142 - Drug target pathways : 209
Showing 1 to 5 of 5 trials
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2008-004919-36-AT (EUCTR) | 20/05/200920090520 | 10/11/200820081110 | A Phase 2B, Multi-center, Randomized, Double- blind, Parallel Group, Placebo-controlled, Dose Ranging Study Comparing the Efficacy, Safety, and Pharmacokinetics of Intravenous Infusions of ABT - 874 vs. Placebo in Subjects with Moderately to Severely Active Crohn's Disease A Phase 2B, Multi-center, Randomized, Double- blind, Parallel Group, Placebo-controlled, Dose Rangin ... | A Phase 2B, Multi-center, Randomized, Double- blind, Parallel Group, Placebo-controlled, Dose Ranging Study Comparing the Efficacy, Safety, and Pharmacokinetics of Intravenous Infusions of ABT - 874 vs. Placebo in Subjects with Moderately to Severely Active Crohn's Disease A Phase 2B, Multi-center, Randomized, Double- blind, Parallel Group, Placebo-controlled, Dose Rangin ... | Crohn's disease MedDRA version: 9.1;Level: LLT;Classification code 10011401;Term: Crohn's disease | Product Name: ABT-874 Product Code: ABT-874 Other descriptive name: J695, BSF 415977 (formerly LU415977), WAY-165772, A-796874.0 Product Name: ABT-874 Product Code: ABT-874 Other descriptive name: J695, BSF 415977 (formerly LU41597 ... | Abbott | NULL | Not Recruiting | Female: yes Male: yes | 225 | Phase 2 | Denmark;Austria;Sweden | ||
| 2 | EUCTR2008-004919-36-SE (EUCTR) | 11/03/200920090311 | 11/12/200820081211 | A Phase 2B, Multi-center, Randomized, Double- blind, Parallel Group, Placebo-controlled, Dose Ranging Study Comparing the Efficacy, Safety, and Pharmacokinetics of Intravenous Infusions of ABT - 874 vs. Placebo in Subjects with Moderately to Severely Active Crohn's Disease A Phase 2B, Multi-center, Randomized, Double- blind, Parallel Group, Placebo-controlled, Dose Rangin ... | A Phase 2B, Multi-center, Randomized, Double- blind, Parallel Group, Placebo-controlled, Dose Ranging Study Comparing the Efficacy, Safety, and Pharmacokinetics of Intravenous Infusions of ABT - 874 vs. Placebo in Subjects with Moderately to Severely Active Crohn's Disease A Phase 2B, Multi-center, Randomized, Double- blind, Parallel Group, Placebo-controlled, Dose Rangin ... | Crohn's disease MedDRA version: 9.1;Level: LLT;Classification code 10011401;Term: Crohn's disease | Product Name: ABT-874 Product Code: ABT-874 INN or Proposed INN: None Other descriptive name: J695, BSF 415977 (formerly LU415977), WAY-165772, A-796874.0 Product Name: ABT-874 Product Code: ABT-874 INN or Proposed INN: None Other descriptive name: J695, BSF ... | Abbott | NULL | Not Recruiting | Female: yes Male: yes | 225 | Phase 2 | Denmark;Austria;Sweden | ||
| 3 | EUCTR2008-004919-36-DK (EUCTR) | 23/01/200920090123 | 18/12/200820081218 | A Phase 2B, Multi-center, Randomized, Double- blind, Parallel Group, Placebo-controlled, Dose Ranging Study Comparing the Efficacy, Safety, and Pharmacokinetics of Intravenous Infusions of ABT - 874 vs. Placebo in Subjects with Moderately to Severely Active Crohn's Disease A Phase 2B, Multi-center, Randomized, Double- blind, Parallel Group, Placebo-controlled, Dose Rangin ... | A Phase 2B, Multi-center, Randomized, Double- blind, Parallel Group, Placebo-controlled, Dose Ranging Study Comparing the Efficacy, Safety, and Pharmacokinetics of Intravenous Infusions of ABT - 874 vs. Placebo in Subjects with Moderately to Severely Active Crohn's Disease A Phase 2B, Multi-center, Randomized, Double- blind, Parallel Group, Placebo-controlled, Dose Rangin ... | Crohn's disease MedDRA version: 9.1;Level: LLT;Classification code 10011401;Term: Crohn's disease | Product Name: ABT-874 Product Code: ABT-874 INN or Proposed INN: None Other descriptive name: J695, BSF 415977 (formerly LU415977), WAY-165772, A-796874.0 Product Name: ABT-874 Product Code: ABT-874 INN or Proposed INN: None Other descriptive name: J695, BSF ... | Abbott | NULL | Not Recruiting | Female: yes Male: yes | 225 | Phase 2 | Denmark;Austria;Sweden | ||
| 4 | EUCTR2008-004919-36-BE (EUCTR) | 20/01/200920090120 | 14/11/200820081114 | A Phase 2B, Multi-center, Randomized, Double- blind, Parallel Group, Placebo-controlled, Dose Ranging Study Comparing the Efficacy, Safety, and Pharmacokinetics of Intravenous Infusions of ABT - 874 vs. Placebo in Subjects with Moderately to Severely Active Crohn's Disease A Phase 2B, Multi-center, Randomized, Double- blind, Parallel Group, Placebo-controlled, Dose Rangin ... | A Phase 2B, Multi-center, Randomized, Double- blind, Parallel Group, Placebo-controlled, Dose Ranging Study Comparing the Efficacy, Safety, and Pharmacokinetics of Intravenous Infusions of ABT - 874 vs. Placebo in Subjects with Moderately to Severely Active Crohn's Disease A Phase 2B, Multi-center, Randomized, Double- blind, Parallel Group, Placebo-controlled, Dose Rangin ... | Crohn's disease MedDRA version: 9.1;Level: LLT;Classification code 10011401;Term: Crohn's disease | Product Name: ABT-874 Product Code: ABT-874 INN or Proposed INN: None Other descriptive name: J695, BSF 415977 (formerly LU415977), WAY-165772, A-796874.0 Product Name: ABT-874 Product Code: ABT-874 INN or Proposed INN: None Other descriptive name: J695, BSF ... | Abbott | NULL | Not Recruiting | Female: yes Male: yes | 225 | Phase 2 | Belgium;Denmark;Austria;Sweden | ||
| 5 | NCT00007163 (ClinicalTrials.gov) | December 200020001200 | 9/12/200020001209 | Monoclonal Antibody Treatment of Crohn's Disease | A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Safety Study of Two Parallel Dose Levels of Subcutaneously Administered Human Monoclonal Antibody to Interleukin-12 (J695) in Patients With Active Crohn's Disease A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Safety Study of Two Parallel Dose Leve ... | Crohn's Disease | Drug: J695 | National Institute of Allergy and Infectious Diseases (NIAID) | NULL | Completed | N/A | N/A | Both | 40 | Phase 1 | United States |